JAK/STAT signaling in hematological malignancies

Oncogene

Volumn 32, Issue 21, 2013, Pages 2601-2613

  Vainchenker, W ^a,b   Constantinescu, S N ^c,d  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c LUDWIG INSTITUTE FOR CANCER RESEARCH   (Belgium)

^d UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

hematological malignancies; JAK STAT; leukemia

Indexed keywords

FEDRATINIB; INTERLEUKIN 7 RECEPTOR; JANUS KINASE; JANUS KINASE 1; JANUS KINASE 2; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN TYROSINE PHOSPHATASE SHP 1; PROTEIN TYROSINE PHOSPHATASE SHP 2; RUXOLITINIB; SOMATOMEDIN C RECEPTOR; STAT PROTEIN; STAT1 PROTEIN; STAT5 PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; CANCER SURVIVAL; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; EXON; GENE MUTATION; HEMATOLOGIC MALIGNANCY; HUMAN; MYELOFIBROSIS; NONHUMAN; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; T CELL LYMPHOMA; THROMBOCYTOPENIA;

AMINO ACID SUBSTITUTION; ANIMALS; EXONS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HEMATOLOGIC NEOPLASMS; HODGKIN DISEASE; HUMANS; JANUS KINASE 2; MUTATION, MISSENSE; NEOPLASM PROTEINS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION; STAT TRANSCRIPTION FACTORS;

EID: 84878232331     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.347     Document Type: Review

References (223)

1. Velazquez L, Fellous M, Stark GR, Pellegrini S. A protein tyrosine kinase in the interferon alpha/beta signaling pathway. Cell 1992; 70: 313-322.
2. Darnell Jr JE, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994; 264: 1415-1421.
3. Remy I, Wilson IA, Michnick SW. Erythropoietin receptor activation by a ligand-induced conformation change. Science 1999; 283: 990-993.
4. Constantinescu SN, Keren T, Socolovsky M, Nam H, Henis YI, Lodish HF. Ligand-independent oligomerization of cell-surface erythropoietin receptor is mediated by the transmembrane domain. Proc Natl Acad Sci USA 2001; 98: 4379-4384.
5. Constantinescu SN, Huang LJ, Nam H, Lodish HF. The erythropoietin receptor cytosolic juxtamembrane domain contains an essential, precisely oriented, hydrophobic motif. Mol Cell 2001; 7: 377-385.
6. Brown RJ, Adams JJ, Pelekanos RA, Wan Y, McKinstry WJ, Palethorpe K et al. Model for growth hormone receptor activation based on subunit rotation within a receptor dimer. Nat Struct Mol Biol 2005; 12: 814-821.
7. Thomas C, Moraga I, Levin D, Krutzik PO, Podoplelova Y, Trejo A et al. Structural linkage between ligand discrimination and receptor activation by type I interferons. Cell 2011; 146: 621-632.
8. Ihle JN. The Janus protein tyrosine kinase family and its role in cytokine signaling. Adv Immunol 1995; 60: 1-35.
9. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C et al. Stat3 as an oncogene. Cell 1999; 98: 295-303.
10. Levy DE, Darnell Jr JE. Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol 2002; 3: 651-662.
11. Migone TS, Lin JX, Cereseto A, Mulloy JC, O'Shea JJ, Franchini G et al. Con-stitutively activated Jak-STAT pathway in T cells transformed with HTLV-I. Science 1995; 269: 79-81.
12. Weber-Nordt RM, Egen C, Wehinger J, Ludwig W, Gouilleux-Gruart V, Mertelsmann R et al. Constitutive activation of STAT proteins in primary lymphoid and myeloid leukemia cells and in Epstein-Barr virus (EBV)-related lymphoma cell lines. Blood 1996; 88: 809-816.
13. Xia Z, Baer MR, Block AW, Baumann H, Wetzler M. Expression of signal transducers and activators of transcription proteins in acute myeloid leukemia blasts. Cancer Res 1998; 58: 3173-3180.
14. Buettner R, Mora LB, Jove R. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res 2002; 8: 945-954.
15. Lacronique V, Boureux A, Valle VD, Poirel H, Quang CT, Mauchauffe M et al. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science 1997; 278: 1309-1312.
16. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054-1061.
17. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434: 1144-1148.
18. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352: 1779-1790.
19. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombo-cythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7: 387-397.
20. Flex E, Petrangeli V, Stella L, Chiaretti S, Hornakova T, Knoops L et al. Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia. J Exp Med 2008; 205: 751-758.
21. Tomasson MH, Xiang Z, Walgren R, Zhao Y, Kasai Y, Miner T et al. Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia. Blood 2008; 111: 4797-4808.
22. Xiang Z, Zhao Y, Mitaksov V, Fremont DH, Kasai Y, Molitoris A et al. Identification of somatic JAK1 mutations in patients with acute myeloid leukemia. Blood 2008; 111: 4809-4812.
23. Mullighan CG, Zhang J, Harvey RC, Collins-Underwood JR, Schulman BA, Phillips LA et al. JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc Natl Acad Sci USA 2009; 106: 9414-9418.
24. Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, Gozo M et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 2006; 3: e270.
25. Mullighan CG, Collins-Underwood JR, Phillips LA, Loudin MG, Liu W, Zhang J et al. Rearrangement of CRLF2 in B-progenitor-and Down syndrome-associated acute lymphoblastic leukemia. Nat Genet 2009; 41: 1243-1246.
26. Russell LJ, Capasso M, Vater I, Akasaka T, Bernard OA, Calasanz MJ et al. Deregulated expression of cytokine receptor gene, CRLF2, is involved in lym-phoid transformation in B-cell precursor acute lymphoblastic leukemia. Blood 2009; 114: 2688-2698.
27. Zenatti PP, Ribeiro D, Li W, Zuurbier L, Silva MC, Paganin M et al. Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia. Nat Genet 2011; 43: 932-939.
28. Oh ST, Simonds EF, Jones C, Hale MB, Goltsev Y, Gibbs Jr KD et al. Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. Blood 2010; 116: 988-992.
29. Watowich SS, Wu H, Socolovsky M, Klingmuller U, Constantinescu SN, Lodish HF. Cytokine receptor signal transduction and the control of hematopoietic cell development. Annu Rev Cell Dev Biol 1996; 12: 91-128.
30. Huang LJ, Constantinescu SN, Lodish HF. The N-terminal domain of Janus kinase 2 is required for Golgi processing and cell surface expression of erythropoietin receptor. Mol Cell 2001; 8: 1327-1338.
31. Radtke S, Hermanns HM, Haan C, Schmitz-Van De Leur H, Gascan H, Heinrich PC et al. Novel role of Janus kinase 1 in the regulation of oncostatin M receptor surface expression. J Biol Chem 2002; 277: 11297-11305.
32. Ragimbeau J, Dondi E, Alcover A, Eid P, Uze G, Pellegrini S. The tyrosine kinase Tyk2 controls IFNAR1 cell surface expression. EMBO J. 2003; 22: 537-547.
33. Royer Y, Staerk J, Costuleanu M, Courtoy PJ, Constantinescu SN. Janus kinases affect thrombopoietin receptor cell surface localization and stability. J Biol Chem 2005; 280: 27251-27261.
34. Syed RS, Reid SW, Li C, Cheetham JC, Aoki KH, Liu B et al. Efficiency of signalling through cytokine receptors depends critically on receptor orientation. Nature 1998; 395: 511-516.
35. Vainchenker W, Dusa A, Constantinescu SN. JAKs in pathology: role of Janus kinases in hematopoietic malignancies and immunodeficiencies. Semin Cell Dev Biol 2008; 19: 385-393.
36. Witthuhn BA, Quelle FW, Silvennoinen O, Yi T, Tang B, Miura O et al. JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin. Cell 1993; 74: 227-236.
37. Drachman JG, Millett KM, Kaushansky K. Thrombopoietin signal transduction requires functional JAK2, not TYK2. J Biol Chem 1999; 274: 13480-13484.
38. Touw IP, van de Geijn GJ. Granulocyte colony-stimulating factor and its receptor in normal myeloid cell development, leukemia and related blood cell disorders. Front Biosci 2007; 12: 800-815.
39. Shimoda K, Feng J, Murakami H, Nagata S, Watling D, Rogers NC et al. Jak1 plays an essential role for receptor phosphorylation and Stat activation in response to granulocyte colony-stimulating factor. Blood 1997; 90: 597-604.
40. Sattler M, Durstin MA, Frank DA, Okuda K, Kaushansky K, Salgia R et al. The thrombopoietin receptor c-MPL activates JAK2 and TYK2 tyrosine kinases. Exp Hematol 1995; 23: 1040-1048.
41. Drachman JG, Kaushansky K. Dissecting the thrombopoietin receptor: functional elements of the Mpl cytoplasmic domain. Proc Natl Acad Sci USA 1997; 94: 2350-2355.
42. Constantinescu SN, Ghaffari S, Lodish HF. The Erythropoietin Receptor: Structure, Activation and Intracellular Signal Transduction. Trends Endocrinol Metab 1999; 10: 18-23.
43. van de Geijn GJ, Gits J, Aarts LH, Heijmans-Antonissen C, Touw IP. G-CSF receptor truncations found in SCN/AML relieve SOCS3-controlled inhibition of STAT5 but leave suppression of STAT3 intact. Blood 2004; 104: 667-674.
44. Liao W, Lin JX, Leonard WJ. IL-2 family cytokines: new insights into the complex roles of IL-2 as a broad regulator of T helper cell differentiation. Curr Opin Immunol 2011; 23: 598-604.
45. Ghoreschi K, Laurence A, O'Shea JJ. Janus kinases in immune cell signaling. Immunol Rev 2009; 228: 273-287.
46. Haan C, Rolvering C, Raulf F, Kapp M, Druckes P, Thoma G et al. Jak1 has a dominant role over Jak3 in signal transduction through gammac-containing cytokine receptors. Chem Biol 2011; 18: 314-323.
47. Demoulin JB, Van Roost E, Stevens M, Groner B, Renauld JC. Distinct roles for STAT1, STAT3, and STAT5 in differentiation gene induction and apoptosis inhibition by interleukin-9. J Biol Chem 1999; 274: 25855-25861.
48. Verdier F, Walrafen P, Hubert N, Chretien S, Gisselbrecht S, Lacombe C et al. Proteasomes regulate the duration of erythropoietin receptor activation by controlling down-regulation of cell surface receptors. J Biol Chem 2000; 275: 18375-18381.
49. Gross AW, Lodish HF. Cellular trafficking and degradation of erythropoietin and novel erythropoiesis stimulating protein (NESP). J Biol Chem 2006; 281: 2024-2032.
50. Irandoust MI, Aarts LH, Roovers O, Gits J, Erkeland SJ, Touw IP. Suppressor of cytokine signaling 3 controls lysosomal routing of G-CSF receptor. EMBO J 2007; 26: 1782-1793.
51. Hitchcock IS, Chen MM, King JR, Kaushansky K. YRRLmotifs in the cytoplasmic domain of the thrombopoietin receptor regulate receptor internalization and degradation. Blood 2008; 112: 2222-2231.
52. Marijanovic Z, Ragimbeau J, Kumar KG, Fuchs SY, Pellegrini S. TYK2 activity promotes ligand-induced IFNAR1 proteolysis. Biochem J 2006; 397: 31-38.
53. Klingmuller U, Lorenz U, Cantley LC, Neel BG, Lodish HF. Specific recruitment of SH-PTP1 to the erythropoietin receptor causes inactivation of JAK2 and termination of proliferative signals. Cell 1995; 80: 729-738.
54. Sasaki A, Yasukawa H, Shouda T, Kitamura T, Dikic I, Yoshimura A. CIS3/SOCS-3 suppresses erythropoietin (EPO) signaling by binding the EPO receptor and JAK2. J Biol Chem 2000; 275: 29338-29347.
55. Wang Q, Miyakawa Y, Fox N, Kaushansky K. Interferon-alpha directly represses megakaryopoiesis by inhibiting thrombopoietin-induced signaling through induction of SOCS-1. Blood 2000; 96: 2093-2099.
56. Jegalian AG, Wu H. Differential roles of SOCS family members in EpoR signal transduction. J Interferon Cytokine Res 2002; 22: 853-860.
57. Hortner M, Nielsch U, Mayr LM, Heinrich PC, Haan S. A new high affinity binding site for suppressor of cytokine signaling-3 on the erythropoietin receptor. Eur J Biochem 2002; 269: 2516-2526.
58. Chaligne R, Tonetti C, Besancenot R, Marty C, Kiladjian JJ, Socie G et al. SOCS3 inhibits TPO-stimulated, but not spontaneous, megakaryocytic growth in primary myelofibrosis. Leukemia 2009; 23: 1186-1190.
59. Palvimo JJ. PIAS proteins as regulators of small ubiquitin-related modifier (SUMO) modifications and transcription. Biochem Soc Trans 2007; 35(Pt 6): 1405-1408.
60. Zhou S, Si J, Liu T, DeWille JW. PIASy represses CCAAT/enhancer-binding protein delta (C/EBPdelta) transcriptional activity by sequestering C/EBPdelta to the nuclear periphery. J Biol Chem 2008; 283: 20137-20148.
61. Yoshimura A, Longmore G, Lodish HF. Point mutation in the exoplasmic domain of the erythropoietin receptor resulting in hormone-independent activation and tumorigenicity. Nature 1990; 348: 647-649.
62. Alexander WS, Metcalf D, Dunn AR. Point mutations within a dimer interface homology domain of c-Mpl induce constitutive receptor activity and tumor-igenicity. EMBO J 1995; 14: 5569-5578.
63. Longmore G, Watowich S, Pharr P, Neumann D, Lodish H. Activation of the erythropoietin receptor and leukemia induction in mice. Leukemia 1993; 7(Suppl 2): S113-S116.
64. Peeters P, Raynaud SD, Cools J, Wlodarska I, Grosgeorge J, Philip P et al. Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia. Blood 1997; 90: 2535-2540.
65. Nguyen MH, Ho JM, Beattie BK, Barber DL. TEL-JAK2 mediates constitutive activation of the phosphatidylinositol 3'-kinase/protein kinase B signaling pathway. J Biol Chem 2001; 276: 32704-32713.
66. Schwaller J, Frantsve J, Aster J, Williams IR, Tomasson MH, Ross TS et al. Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo-and lymphoproliferative disease in mice by retro-virally transduced TEL/JAK2 fusion genes. EMBO J 1998; 17: 5321-5333.
67. Kennedy JA Barabe F, Patterson BJ, Bayani J, JA Squire, Barber DL et al. Expression of TEL-JAK2 in primary human hematopoietic cells drives ery-thropoietin-independent erythropoiesis and induces myelofibrosis in vivo. Proc Natl Acad Sci USA 2006; 103: 16930-16935.
68. Reiter A, Walz C, Watmore A, Schoch C, Blau I, Schlegelberger B et al. The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2. Cancer Res 2005; 65: 2662-2667.
69. Murati A, Gelsi-Boyer V, Adelaide J, Perot C, Talmant P, Giraudier S et al. PCM1-JAK2 fusion in myeloproliferative disorders and acute erythroid leukemia with t(8;9) translocation. Leukemia 2005; 19: 1692-1696.
70. Adelaide J, Perot C, Gelsi-Boyer V, Pautas C, Murati A, Copie-Bergman C et al. A t(8;9) translocation with PCM1-JAK2 fusion in a patient with T-cell lymphoma. Leukemia 2006; 20: 536-537.
71. Cirmena G, Aliano S, Fugazza G, Bruzzone R, Garuti A, Bocciardi R et al. A BCR-JAK2 fusion gene as the result of a t(9;22)(p24;q11) in a patient with acute myeloid leukemia. Cancer Genet Cytogenet 2008; 183: 105-108.
72. Poitras JL, Dal Cin P, Aster JC, Deangelo DJ, Morton CC. Novel SSBP2-JAK2 fusion gene resulting from a t(5;9)(q14.1;p24.1) in pre-B acute lymphocytic leukemia. Genes Chromosomes Cancer 2008; 47: 884-889.
73. Nebral K, Denk D, Attarbaschi A, Konig M, Mann G, Haas OA et al. Incidence and diversity of PAX5 fusion genes in childhood acute lymphoblastic leukemia. Leukemia 2009; 23: 134-143.
74. Van Roosbroeck K, Cox L, Tousseyn T, Lahortiga I, Gielen O, Cauwelier B et al. JAK2 rearrangements, including the novel SEC31A-JAK2 fusion, are recurrent in classical Hodgkin lymphoma. Blood 2011; 117: 4056-4064.
75. Knoops L, Hornakova T, Royer Y, Constantinescu SN, Renauld JC. JAK kinases overexpression promotes in vitro cell transformation. Oncogene 2008; 27: 1511-1519.
76. Navarro A, Diaz T, Martinez A, Gaya A, Pons A, Gel B et al. Regulation of JAK2 by miR-135a: prognostic impact in classic Hodgkin lymphoma. Blood 2009; 114: 2945-2951.
77. Weniger MA, Melzner I, Menz CK, Wegener S, Bucur AJ, Dorsch K et al. Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation. Oncogene 2006; 25: 2679-2684.
78. Kleppe M, Tousseyn T, Geissinger E, Kalender Atak Z, Aerts S, Rosenwald A et al. Mutation analysis of the tyrosine phosphatase PTPN2 in Hodgkin's lymphoma and T-cell non-Hodgkin's lymphoma. Haematologica 2011; 96: 1723-1727.
79. Tefferi A. Classification, diagnosis and management of myeloproliferative disorders in the JAK2V617F era. Hematology Am Soc Hematol Educ Program 2006 240-245.
80. Kralovics R, Guan Y, Prchal JT. Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera. Exp Hematol 2002; 30: 229-236.
81. Ungureanu D, Wu J, Pekkala T, Niranjan Y, Young C, Jensen ON et al. The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling. Nat Struct Mol Biol 2011; 18: 971-976.
82. Argetsinger LS, Kouadio JL, Steen H, Stensballe A, Jensen ON, Carter-Su C. Autophosphorylation of JAK2 on tyrosines 221 and 570 regulates its activity. Mol Cell Biol 2004; 24: 4955-4967.
83. Feener EP, Rosario F, Dunn SL, Stancheva Z, Myers Jr MG. Tyrosine phosphor-ylation of Jak2 in the JH2 domain inhibits cytokine signaling. Mol Cell Biol 2004; 24: 4968-4978.
84. Ishida-Takahashi R, Rosario F, Gong Y, Kopp K, Stancheva Z, Chen X et al. Phosphorylation of Jak2 on Ser(523) inhibits Jak2-dependent leptin receptor signaling. Mol Cell Biol 2006; 26: 4063-4073.
85. Lu X, Huang LJ, Lodish HF. Dimerization by a cytokine receptor is necessary for constitutive activation of JAK2V617F. J Biol Chem 2008; 283: 5258-5266.
86. Chen E, Beer PA, Godfrey AL, Ortmann CA, Li J, Costa-Pereira AP et al. Distinct clinical phenotypes associated with JAK2V617F reflect differential STAT1 signaling. Cancer Cell 2010; 18: 524-535.
87. Staerk J, Kallin A, Demoulin JB, Vainchenker W. JAK1 Constantinescu SN and Tyk2 activation by the homologous polycythemia vera JAK2 V617F mutation: cross-talk with IGF1 receptor. J Biol Chem 2005; 280: 41893-41899.
88. Lacout C, Pisani DF, Tulliez M, Gachelin FM, Vainchenker W, Villeval JL. JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood 2006; 108: 1652-1660.
89. Tiedt R, Hao-Shen H, Sobas MA, Looser R, Dirnhofer S, Schwaller J et al. Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. Blood 2008; 111: 3931-3940.
90. Wernig G, Gonneville JR, Crowley BJ, Rodrigues MS, Reddy MM, Hudon HE et al. The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes. Blood 2008; 111: 3751-3759.
91. Akada H, Yan D, Zou H, Fiering S, Hutchison RE, Mohi MG. Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease. Blood 2010; 115: 3589-3597.
92. Li J, Spensberger D, Ahn JS, Anand S, Beer PA, Ghevaert C et al. JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia. Blood 2010; 116: 1528-1538.
93. Marty C, Lacout C, Martin A, Hasan S, Jacquot S, Birling MC et al. Myeloproli-ferative neoplasm induced by constitutive expression of JAK2V617F in knock-in mice. Blood 2010; 116: 783-787.
94. Mullally A, Lane SW, Ball B, Megerdichian C, Okabe R, Al-Shahrour F et al. Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells. Cancer Cell 2010; 17: 584-596.
95. Scott LM, Scott MA, Campbell PJ, Green AR. Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia. Blood 2006; 108: 2435-2437.
96. Dupont S, Masse A, James C, Teyssandier I, Lecluse Y, Larbret F et al. The JAK2 617V4F mutation triggers erythropoietin hypersensitivity and terminal ery-throid amplification in primary cells from patients with polycythemia vera. Blood 2007; 110: 1013-1021.
97. Teofili L, Martini M, Cenci T, Petrucci G, Torti L, Storti S et al. Different STAT-3 and STAT-5 phosphorylation discriminates among Ph-negative chronic myeloproli-ferative diseases and is independent of the V617F JAK-2 mutation. Blood 2007; 110: 354-359.
98. Ugo V, Marzac C, Teyssandier I, Larbret F, Lecluse Y, Debili N et al. Multiple signaling pathways are involved in erythropoietin-independent differentiation of erythroid progenitors in polycythemia vera. Exp Hematol 2004; 32: 179-187.
99. Garcon L, Rivat C, James C, Lacout C, Camara-Clayette V, Ugo V et al. Constitutive activation of STAT5 and Bcl-xL overexpression can induce endogenous erythroid colony formation in human primary cells. Blood 2006; 108: 1551-1554.
100. Walz C, Ahmed W, Lazarides K, Betancur M, Patel N, Hennighausen L et al. Essential role for Stat5a/b in myeloproliferative neoplasms induced by BCR-ABL1 and JAK2(V617F) in mice. Blood 2012; 119: 3550-3560.
101. Yan D, Hutchison RE, Mohi G. Critical requirement for Stat5 in a mouse model of polycythemia vera. Blood 2012; 119: 3539-3549.
102. Yao Z, Cui Y, Watford WT, Bream JH, Yamaoka K, Hissong BD et al. Stat5a/b are essential for normal lymphoid development and differentiation. Proc Natl Acad Sci USA 2006; 103: 1000-1005.
103. Hennighausen L, Robinson GW. Interpretation of cytokine signaling through the transcription factors STAT5A and STAT5B. Genes Dev 2008; 22: 711-721.
104. Harrison C, Verstovsek S, McMullin MF, Mesa R. Janus kinase Inhibition and its effect upon the therapeutic landscape for myelofibrosis: from palliation to cure? Br J Haematol 2012; 157: 426-437.
105. Tefferi A. Challenges facing JAK inhibitor therapy for myeloproliferative neoplasms. N Engl J Med 2012; 366: 844-846.
106. Tefferi AJAK. inhibitors for myeloproliferative neoplasms: clarifying facts from myths. Blood 2012; 119: 2721-2730.
107. Carbuccia N, Murati A, Trouplin V, Brecqueville M, Adelaide J, Rey J et al. Mutations of ASXL1 gene in myeloproliferative neoplasms. Leukemia 2009; 23: 2183-2186.
108. Delhommeau F, Dupont S, Della Valle V, James C, Trannoy S, Masse A et al. Mutation in TET2 in myeloid cancers. N Engl J Med 2009; 360: 2289-2301.
109. Yoshida K, Sanada M, Shiraishi Y, Nowak D, Nagata Y, Yamamoto R et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 2011; 478: 64-69.
110. Papaemmanuil E, Cazzola M, Boultwood J, Malcovati L, Vyas P, Bowen D et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med 2011; 365: 1384-1395.
111. Malcovati L, Della Porta MG, Pietra D, Boveri E, Pellagatti A, Galli A et al. Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Blood 2009; 114: 3538-3545.
112. Hookham MB, Elliott J, Suessmuth Y, Staerk J, Ward AC, Vainchenker W et al. The myeloproliferative disorder-associated JAK2 V617F mutant escapes negative regulation by suppressor of cytokine signaling 3. Blood 2007; 109: 4924-4929.
113. Liu F, Zhao X, Perna F, Wang L, Koppikar P, Abdel-Wahab O et al. JAK2V617F-mediated phosphorylation of PRMT5 downregulates its methyltransferase activity and promotes myeloproliferation. Cancer Cell 2011; 19: 283-294.
114. Wrighton KH. Cell signalling: PRMT5 restricts ERK activity. Nat Rev Mol Cell Biol 2011; 12: 689.
115. Kanade SR, Eckert RL. Protein arginine methyltransferase 5 (PRMT5) signaling suppresses protein kinase Cdelta-and p38delta-dependent signaling and kera-tinocyte differentiation. J Biol Chem 2012; 287: 7313-7323.
116. Dawson MA, Bannister AJ, Gottgens B, Foster SD, Bartke T, Green AR et al. JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin. Nature 2009; 461: 819-822.
117. Besancenot R, Chaligne R, Tonetti C, Pasquier F, Marty C, Lecluse Y et al. A senescence-like cell-cycle arrest occurs during megakaryocytic maturation: implications for physiological and pathological megakaryocytic proliferation. PLoS Biol 2010; 8: 9.
118. Pecquet C, Diaconu CC, Staerk J, Girardot M, Marty C, Royer Y et al. Thrombo-poietin receptor down-modulation by JAK2 V617F: restoration of receptor levels by inhibitors of pathologic JAK2 signaling and of proteasomes. Blood 2012; 119: 4625-4635.
119. Marubayashi S, Koppikar P, Taldone T, Abdel-Wahab O, West N, Bhagwat N et al. HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans. J Clin Invest 2010; 120: 3578-3593.
120. Dusa A, Mouton C, Pecquet C, Herman M, Constantinescu SN. JAK2 V617F constitutive activation requires JH2 residue F595: a pseudokinase domain target for specific inhibitors. PLoS One 2010; 5: e11157.
121. Dusa A, Staerk J, Elliott J, Pecquet C, Poirel HA, Johnston JA et al. Substitution of pseudokinase domain residue Val-617 by large non-polar amino acids causes activation of JAK2. J Biol Chem 2008; 283: 12941-12948.
122. Ma W, Kantarjian H, Zhang X, Yeh CH, Zhang ZJ, Verstovsek S et al. Mutation profile of JAK2 transcripts in patients with chronic myeloproliferative neoplasias. J Mol Diagn 2009; 11: 49-53.
123. Mead AJ, Rugless MJ, Jacobsen SE, Schuh A. Germline JAK2 mutation in a family with hereditary thrombocytosis. N Engl J Med 2012; 366: 967-969.
124. Scott LM, Tong W, Levine RL, Scott MA, Beer PA, Stratton MR et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 2007; 356: 459-468.
125. Klampfl T, Harutyunyan A, Berg T, Gisslinger B, Schalling M, Bagienski K et al. Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression. Blood 2011; 118: 167-176.
126. Passamonti F, Elena C, Schnittger S, Skoda RC, Green AR, Girodon F et al. Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations. Blood 2011; 117: 2813-2816.
127. Malinge S, Ben-Abdelali R, Settegrana C, Radford-Weiss I, Debre M, Beldjord K et al. Novel activating JAK2 mutation in a patient with Down syndrome and B-cell precursor acute lymphoblastic leukemia. Blood 2007; 109: 2202-2204.
128. Kearney L, Gonzalez De Castro D, Yeung J, Procter J, Horsley SW, Eguchi-Ishimae M et al. Specific JAK2 mutation (JAK2R683) and multiple gene deletions in Down syndrome acute lymphoblastic leukemia. Blood 2009; 113: 646-648.
129. Gaikwad A, Rye CL, Devidas M, Heerema NA, Carroll AJ, Izraeli S et al. Prevalence and clinical correlates of JAK2 mutations in Down syndrome acute lympho-blastic leukaemia. Br J Haematol 2009; 144: 930-932.
130. Mullighan CG. New strategies in acute lymphoblastic leukemia: translating advances in genomics into clinical practice. Clin Cancer Res 2011; 17: 396-400.
131. Chen IM, Harvey RC, Mullighan CG, Gastier-Foster J, Wharton W, Kang H et al. Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children's Oncology Group study. Blood 2012; 119: 3512-3522.
132. Malinge S, Ragu C, Della-Valle V, Pisani D, Constantinescu SN, Perez C et al. Activating mutations in human acute megakaryoblastic leukemia. Blood 2008; 112: 4220-4226.
133. Zhang J, Ding L, Holmfeldt L, Wu G, Heatley SL, Payne-Turner D et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 2012; 481: 157-163.
134. Jeong EG, Kim MS, Nam HK, Min CK, Lee S, Chung YJ et al. Somatic mutations of JAK1 and JAK3 in acute leukemias and solid cancers. Clin Cancer Res 2008; 14: 3716-3721.
135. Hornakova T, Staerk J, Royer Y, Flex E, Tartaglia M, Constantinescu SN et al. Acute lymphoblastic leukemia-associated JAK1 mutants activate the Janus kinase/STAT pathway via interleukin-9 receptor alpha homodimers. J Biol Chem 2009; 284: 6773-6781.
136. Kleppe M, Soulier J, Asnafi V, Mentens N, Hornakova T, Knoops L et al. PTPN2 negatively regulates oncogenic JAK1 in T-cell acute lymphoblastic leukemia. Blood 2011; 117: 7090-7098.
137. Porcu M, Kleppe M, Gianfelici V, Geerdens E, De Keersmaecker K, Tartaglia M et al. Mutation of the receptor tyrosine phosphatase PTPRC (CD45) in T-cell acute lymphoblastic leukemia. Blood 2012; 119: 4476-4479.
138. Kameda T, Shide K, Shimoda HK, Hidaka T, Kubuki Y, Katayose K et al. Absence of gain-of-function JAK1 and JAK3 mutations in adult T cell leukemia/lymphoma. Int J Hematol 2010; 92: 320-325.
139. Elliott NE, Cleveland SM, Grann V, Janik J, Waldmann TA, Dave UP. FERM domain mutations induce gain of function in JAK3 in adult T-cell leukemia/lymphoma. Blood 2011; 118: 3911-3921.
140. Riera L, Lasorsa E, Bonello L, Sismondi F, Tondat F, Di Bello C et al. Description of a novel Janus kinase 3 P132A mutation in acute megakaryoblastic leukemia and demonstration of previously reported Janus kinase 3 mutations in normal subjects. Leuk Lymphoma 2011; 52: 1742-1750.
141. Walters DK, Mercher T, Gu TL, O'Hare T, Tyner JW, Loriaux M et al. Activating alleles of JAK3 in acute megakaryoblastic leukemia. Cancer Cell 2006; 10: 65-75.
142. Kaminker JS, Zhang Y, Waugh A, Haverty PM, Peters B, Sebisanovic D et al. Distinguishing cancer-associated missense mutations from common polymorphisms. Cancer Res 2007; 67: 465-473.
143. Jones AV, Chase A, Silver RT, Oscier D, Zoi K, Wang YL et al. JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms. Nat Genet 2009; 41: 446-449.
144. Olcaydu D, Harutyunyan A, Jager R, Berg T, Gisslinger B, Pabinger I et al. A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms. Nat Genet 2009; 41: 450-454.
145. Kilpivaara O, Mukherjee S, Schram AM, Wadleigh M, Mullally A, Ebert BL et al. A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms. Nat Genet 2009; 41: 455-459.
146. Ritz O, Guiter C, Castellano F, Dorsch K, Melzner J, Jais JP et al. Recurrent mutations of the STAT6 DNA binding domain in primary mediastinal B-cell lymphoma. Blood 2009; 114: 1236-1242.
147. Baus D, Nonnenmacher F, Jankowski S, Doring C, Brautigam C, Frank M et al. STAT6 and STAT1 are essential antagonistic regulators of cell survival in classical Hodgkin lymphoma cell line. Leukemia 2009; 23: 1885-1893.
148. Nault JC, Fabre M, Couchy G, Pilati C, Jeannot E, Tran Van Nhieu J et al. GNAS-activating mutations define a rare subgroup of inflammatory liver tumors characterized by STAT3 activation. J Hepatol 2012; 56: 184-191.
149. Koskela HL, Eldfors S, Ellonen P, van Adrichem AJ, Kuusanmaki H, Andersson EI et al. Somatic STAT3 mutations in large granular lymphocytic leukemia. New Engl J Med 2012; 366: 1905-1913.
150. Pardanani AD, Levine RL, Lasho T, Pikman Y, Mesa RA, Wadleigh M et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 2006; 108: 3472-3476.
151. Beer PA, Campbell PJ, Scott LM, Bench AJ, Erber WN, Bareford D et al. MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. Blood 2008; 112: 141-149.
152. Boyd EM, Bench AJ, Goday-Fernandez A, Anand S, Vaghela KJ, Beer P et al. Clinical utility of routine MPL exon 10 analysis in the diagnosis of essential thrombocythaemia and primary myelofibrosis. Br J Haematol 2010; 149: 250-257.
153. Pecquet C, Staerk J, Chaligne R, Goss V, Lee KA, Zhang X et al. Induction of myeloproliferative disorder and myelofibrosis by thrombopoietin receptor W515 mutants is mediated by cytosolic tyrosine 112 of the receptor. Blood 2010; 115: 1037-1048.
154. Staerk J, Lacout C, Sato T, Smith SO, Vainchenker W, Constantinescu SN. An amphipathic motif at the transmembrane-cytoplasmic junction prevents autonomous activation of the thrombopoietin receptor. Blood 2006; 107: 1864-1871.
155. Ding J, Komatsu H, Wakita A, Kato-Uranishi M, Ito M, Satoh A et al. Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin. Blood 2004; 103: 4198-4200.
156. Chaligne R, Tonetti C, Besancenot R, Roy L, Marty C, Mossuz P et al. New mutations of MPL in primitive myelofibrosis: only the MPL W515 mutations promote a G1/S-phase transition. Leukemia 2008; 22: 1557-1566.
157. Hussein K, Bock O, Theophile K, Schulz-Bischof K, Porwit A, Schlue J et al. MPLW515L mutation in acute megakaryoblastic leukaemia. Leukemia 2009; 23: 852-855.
158. Shochat C, Tal N, Bandapalli OR, Palmi C, Ganmore I, te Kronnie G et al. Gain-of-function mutations in interleukin-7 receptor-alpha (IL7R) in childhood acute lymphoblastic leukemias. J Exp Med 2011; 208: 901-908.
159. Hertzberg L, Vendramini E, Ganmore I, Cazzaniga G, Schmitz M, Chalker J et al. Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group. Blood 2010; 115: 1006-1017.
160. Forbes LV, Gale RE, Pizzey A, Pouwels K, Nathwani A, Linch DC. An activating mutation in the transmembrane domain of the granulocyte colony-stimulating factor receptor in patients with acute myeloid leukemia. Oncogene 2002; 21: 5981-5989.
161. Plo I, Zhang Y, Le Couedic JP, Nakatake M, Boulet JM, Itaya M et al. An activating mutation in the CSF3R gene induces a hereditary chronic neutrophilia. J Exp Med 2009; 206: 1701-1707.
162. Beekman R, Touw IP. G-CSF and its receptor in myeloid malignancy. Blood 2010; 115: 5131-5136.
163. Beekman R, Valkhof MG, Sanders MA, van Strien PM, Haanstra JR, Broeders L et al. Sequential gain of mutations in severe congenital neutropenia progressing to acute myeloid leukemia. Blood 2012; 119: 5071-5077.
164. Golub TR, Barker GF, Lovett M, Gilliland DG. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell 1994; 77: 307-316.
165. Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003; 348: 1201-1214.
166. Sternberg DW, Gilliland DG. The role of signal transducer and activator of transcription factors in leukemogenesis. J Clin Oncol 2004; 22: 361-371.
167. Cain JA, Xiang Z, O'Neal J, Kreisel F, Colson A, Luo H et al. Myeloproliferative disease induced by TEL-PDGFRB displays dynamic range sensitivity to Stat5 gene dosage. Blood 2007; 109: 3906-3914.
168. Toffalini F, Demoulin JB. New insights into the mechanisms of hematopoietic cell transformation by activated receptor tyrosine kinases. Blood 2010; 116: 2429-2437.
169. Choudhary C, Muller-Tidow C, Berdel WE, Serve H. Signal transduction of oncogenic Flt3. Int J Hematol 2005; 82: 93-99.
170. Choudhary C, Olsen JV, Brandts C, Cox J, Reddy PN, Bohmer FD et al. Mislocalized activation of oncogenic RTKs switches downstream signaling outcomes. Mol Cell 2009; 36: 326-339.
171. Lasho T, Tefferi A, Pardanani A. Inhibition of JAK-STAT signaling by TG101348: a novel mechanism for inhibition of KITD816V-dependent growth in mast cell leukemia cells. Leukemia 2010; 24: 1378-1380.
172. Brender C, Lovato P, Sommer VH, Woetmann A, Mathiesen AM, Geisler C et al. Constitutive SOCS-3 expression protects T-cell lymphoma against growth inhibition by IFNalpha. Leukemia 2005; 19: 209-213.
173. Rudd CE. Lnk adaptor: novel negative regulator of B cell lymphopoiesis. Sci STKE 2001; 85: pe1.
174. Lu X, Levine R, Tong W, Wernig G, Pikman Y, Zarnegar S et al. Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation. Proc Natl Acad Sci USA 2005; 102: 18962-18967.
175. Tong W, Lodish HF. Lnk inhibits Tpo-mpl signaling and Tpo-mediated mega-karyocytopoiesis. J Exp Med 2004; 200: 569-580.
176. Velazquez L, Cheng AM, Fleming HE, Furlonger C, Vesely S, Bernstein A et al. Cytokine signaling and hematopoietic homeostasis are disrupted in Lnk-defi-cient mice. J Exp Med 2002; 195: 1599-1611.
177. Pardanani A, Lasho T, Finke C, Oh ST, Gotlib J, Tefferi A. LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations. Leukemia 2010; 24: 1713-1718.
178. Bersenev A, Wu C, Balcerek J, Jing J, Kundu M, Blobel GA et al. Lnk constrains myeloproliferative diseases in mice. J Clin Invest 2010; 120: 2058-2069.
179. Krebs DL, Hilton DJ. SOCS: physiological suppressors of cytokine signaling. J Cell Sci 2000; 113(Pt 16): 2813-2819.
180. Calabrese V, Mallette FA, Deschenes-Simard X, Ramanathan S, Gagnon J, Moores A et al. SOCS1 links cytokine signaling to p53 and senescence. Mol Cell 2009; 36: 754-767.
181. Melzner I, Bucur AJ, Bruderlein S, Dorsch K, Hasel C, Barth TF et al. Biallelic mutation of SOCS-1 impairs JAK2 degradation and sustains phospho-JAK2 action in the MedB-1 mediastinal lymphoma line. Blood 2005; 105: 2535-2542.
182. Elliott J, Suessmuth Y, Scott LM, Nahlik K, McMullin MF, Constantinescu SN et al. SOCS3 tyrosine phosphorylation as a potential bio-marker for myeloproliferative neoplasms associated with mutant JAK2 kinases. Haematologica 2009; 94: 576-580.
183. Reddy J, Shivapurkar N, Takahashi T, Parikh G, Stastny V, Echebiri C et al. Differential methylation of genes that regulate cytokine signaling in lymphoid and hematopoietic tumors. Oncogene 2005; 24: 732-736.
184. Teofili L, Martini M, Cenci T, Guidi F, Torti L, Giona F et al. Epigenetic alteration of SOCS family members is a possible pathogenetic mechanism in JAK2 wild type myeloproliferative diseases. Int J Cancer 2008; 123: 1586-1592.
185. Jost E, do ON, Dahl E, Maintz CE, Jousten P, Habets L et al. Epigenetic alterations complement mutation of JAK2 tyrosine kinase in patients with BCR/ABL-nega-tive myeloproliferative disorders. Leukemia 2007; 21: 505-510.
186. Irie-Sasaki J, Sasaki T, Matsumoto W, Opavsky A, Cheng M, Welstead G et al. CD45 is a JAK phosphatase and negatively regulates cytokine receptor signalling. Nature 2001; 409: 349-354.
187. Harashima A, Suzuki M, Okochi A, Yamamoto M, Matsuo Y, Motoda R et al. CD45 tyrosine phosphatase inhibits erythroid differentiation of umbilical cord blood CD34 cells associated with selective inactivation of Lyn. Blood 2002; 100: 4440-4445.
188. Braggio E, Maiolino A, Gouveia ME, Magalhaes R, Souto Filho JT, Garnica M et al. Methylation status of nine tumor suppressor genes in multiple myeloma. Int J Hematol 2010; 91: 87-96.
189. Chim CS, Kwong YL, Liang R. Gene hypermethylation in multiple myeloma: lessons from a cancer pathway approach. Clin Lymphoma Myeloma 2008; 8: 331-339.
190. Liu X, Qu CK. Protein Tyrosine Phosphatase SHP-2 (PTPN11) in Hematopoiesis and Leukemogenesis. J Signal Transduct 2011: 195239.
191. Saur SJ, Sangkhae V, Geddis AE, Kaushansky K, Hitchcock IS. Ubiquitination and degradation of the thrombopoietin receptor c-Mpl. Blood 2010; 115: 1254-1263.
192. Bacher U, Haferlach C, Schnittger S, Kohlmann A, Kern W, Haferlach T. Mutations of the TET2 and CBL genes: novel molecular markers in myeloid malignancies. Ann Hematol 2010; 89: 643-652.
193. Kales SC, Ryan PE, Nau MM, Lipkowitz S. Cbl and human myeloid neoplasms: the Cbl oncogene comes of age. Cancer Res 2010; 70: 4789-4794.
194. Grand FH, Hidalgo-Curtis CE, Ernst T, Zoi K, Zoi C, McGuire C et al. Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloprolifera-tive neoplasms. Blood 2009; 113: 6182-6192.
195. Bommert K, Bargou RC, Stuhmer T. Signalling and survival pathways in multiple myeloma. Eur J Cancer 2006; 42: 1574-1580.
196. Ishikawa H, Tsuyama N, Abroun S, Liu S, Li FJ, Otsuyama K et al. Interleukin-6, CD45 and the src-kinases in myeloma cell proliferation. Leuk Lymphoma 2003; 44: 1477-1481.
197. Levy Y, Tsapis A, Brouet JC. Interleukin-6 antisense oligonucleotides inhibit the growth of human myeloma cell lines. J Clin Invest 1991; 88: 696-699.
198. Li J, Favata M, Kelley JA, Caulder E, Thomas B, Wen X et al. INCB16562, a JAK1/2 selective inhibitor, is efficacious against multiple myeloma cells and reverses the protective effects of cytokine and stromal cell support. Neoplasia 2010; 12: 28-38.
199. Ramakrishnan V, Kimlinger T, Haug J, Timm M, Wellik L, Halling T et al. TG101209, a novel JAK2 inhibitor, has significant in vitro activity in multiple myeloma and displays preferential cytotoxicity for CD45 myeloma cells. Am J Hematol 2010; 85: 675-686.
200. Scuto A, Krejci P, Popplewell L, Wu J, Wang Y, Kujawski M et al. The novel JAK inhibitor AZD1480 blocks STAT3 and FGFR3 signaling, resulting in suppression of human myeloma cell growth and survival. Leukemia 2011; 25: 538-550.
201. Warsch W, Kollmann K, Eckelhart E, Fajmann S, Cerny-Reiterer S, Holbl A et al. High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia. Blood 2011; 117: 3409-3420.
202. Hantschel O, Warsch W, Eckelhart E, Kaupe I, Grebien F, Wagner KU et al. BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia. Nat Chem Biol 2012; 8: 285-293.
203. Ozawa Y, Williams AH, Estes ML, Matsushita N, Boschelli F, Jove R et al. Src family kinases promote AML cell survival through activation of signal transducers and activators of transcription (STAT). Leuk Res 2008; 32: 893-903.
204. Moucadel V, Constantinescu SN. Differential STAT5 signaling by ligand-depen-dent and constitutively active cytokine receptors. J Biol Chem 2005; 280: 13364-13373.
205. Girardot M, Pecquet C, Boukour S, Knoops L, Ferrant A, Vainchenker W et al. miR-28 is a thrombopoietin receptor targeting microRNA detected in a fraction of myeloproliferative neoplasm patient platelets. Blood 2010; 116: 437-445.
206. Pardanani A, Gotlib JR, Jamieson C, Cortes JE, Talpaz M, Stone RM et al. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol 2011; 29: 789-796.
207. Santos FP, Kantarjian HM, Jain N, Manshouri T, Thomas DA, Garcia-Manero G et al. Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. Blood [Clinical Trial, Phase II Research Support, Non-U.S. Gov't] 2010; 115: 1131-1136.
208. Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofi-brosis. New Engl J Med 2010; 363: 1117-1127.
209. Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofi-brosis. N Engl J Med 2010; 363: 1117-1127.
210. Verstovsek S. Janus-activated kinase 2 inhibitors: a new era of targeted therapies providing significant clinical benefit for Philadelphia chromosome-negative myeloproliferative neoplasms. J Clin Oncol 2011; 29: 781-783.
211. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF et al. A doubleblind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012; 366: 799-807.
212. Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 2012; 366: 787-798.
213. Yoshihara H, Arai F, Hosokawa K, Hagiwara T, Takubo K, Nakamura Y et al. Thrombopoietin/MPL signaling regulates hematopoietic stem cell quiescence and interaction with the osteoblastic niche. Cell Stem Cell 2007; 1: 685-697.
214. Qian H, Buza-Vidas N, Hyland CD, Jensen CT, Antonchuk J, Mansson R et al. Critical role of thrombopoietin in maintaining adult quiescent hematopoietic stem cells. Cell Stem Cell 2007; 1: 671-684.
215. de Graaf CA, Kauppi M, Baldwin T, Hyland CD, Metcalf D, Willson TA et al. Regulation of hematopoietic stem cells by their mature progeny. Proc Natl Acad Sci USA 2010; 107: 21689-21694.
216. Rambaldi A, Dellacasa CM, Finazzi G, Carobbio A, Ferrari ML, Guglielmelli P et al. A pilot study of the Histone-Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms. Br J Haematol 2010; 150: 446-455.
217. Hornakova T, Springuel L, Devreux J, Dusa A, Constantinescu SN, Knoops L et al. Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors. Haematologica 2011; 96: 845-853.
218. Deshpande A, Reddy MM, Schade GO, Ray A, Chowdary TK, Griffin JD et al. Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms. Leukemia 2012; 26: 708-715.
219. Weigert O, Lane AA, Bird L, Kopp N, Chapuy B, van Bodegom D et al. Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition. J Exp Med 2012; 209: 259-273.
220. Guglielmelli P, Barosi G, Rambaldi A, Marchioli R, Masciulli A, Tozzi L et al. Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis. Blood 2011; 118: 2069-2076.
221. Lu M, Wang J, Li Y, Berenzon D, Wang X, Mascarenhas J et al. Treatment with the Bcl-xL inhibitor ABT-737 in combination with interferon alpha specifically targets JAK2V617F-positive polycythemia vera hematopoietic progenitor cells. Blood 2010; 116: 4284-4287.
222. Guglielmelli P, Biamonte F, Score J, Hidalgo-Curtis C, Cervantes F, Maffioli M et al. EZH2 mutational status predicts poor survival in myelofibrosis. Blood 2011; 118: 5227-5234.
223. Nelson EA, Walker SR, Weisberg E, Bar-Natan M, Barrett R, Gashin LB et al. The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors. Blood 2011; 117: 3421-3429.